Overview
An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants
Status:
Completed
Completed
Trial end date:
2018-07-27
2018-07-27
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Bristol-Myers SquibbTreatments:
Rifampin
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, pleasevisit www.BMSStudyConnect.com
Inclusion Criteria:
- Healthy participant, as determined by no clinically significant deviation from normal
in medical history, physical examination, ECGs, and clinical laboratory determinations
- Body mass index (BMI)of 18.0to 30.0 kg/m2, inclusive, at screening
Exclusion Criteria:
- Women of childbearing potential
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study treatment administration) gastrointestinal
disease that could affect absorption or history of cholecystectomy
Other protocol defined inclusion/exclusion criteria may apply